Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mild cognitive impairment: a nosological entity?

Thierry Voisin1, Jacques Touchon, Bruno Vellas

  • 1Department of Internal Medicine and Clinical Gerontology, Acute Unit for Alzheimer's Patients, Toulouse University, Toulouse, France. dintilhac.b@chu-toulouse.fr

Current Opinion in Neurology
|May 8, 2004
PubMed
Summary

Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia. Redefining MCI criteria is crucial for developing effective preventive therapies and understanding its link to Alzheimer's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors.

Contemporary clinical trials·2020
Same author

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.

Journal of Alzheimer's disease : JAD·2020
Same author

Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2020
Same author

The genetic architecture of human brainstem structures and their involvement in common brain disorders.

Nature communications·2020
Same author

An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene.

Neurobiology of aging·2020
Same author

Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort.

Journal of the American Medical Directors Association·2020

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) represents a transitional phase between normal aging and dementia.
  • Current MCI criteria are not standardized, leading to heterogeneity in diagnosis and understanding.
  • MCI is considered a potential window for early intervention with preventive therapies.

Purpose of the Study:

  • To review the concept and evolving criteria of mild cognitive impairment.
  • To highlight the heterogeneity within MCI and its implications for diagnosis and treatment.
  • To emphasize the need for redefining MCI criteria for improved therapeutic development.

Main Methods:

  • Literature review of proposed and modified criteria for mild cognitive impairment.
  • Analysis of sources of heterogeneity in MCI, including biological, symptomatic, and clinical course factors.

Related Experiment Videos

  • Examination of proposed classifications for MCI subtypes.

    • Main Results:

    • Mild cognitive impairment is not a definitive diagnosis but an evolving concept.
    • Significant heterogeneity exists within MCI, complicating its role as an Alzheimer's disease predictor.
    • Proposed MCI classifications include amnestic, multiple-domain, and single non-memory subtypes.

    Conclusions:

    • The heterogeneity of mild cognitive impairment necessitates a re-evaluation of diagnostic criteria.
    • Refined MCI criteria are essential for advancing the development of targeted preventive therapies.
    • Further research is needed to establish explicit diagnostic standards for MCI.